

## **REMARKS**

Applicants respectfully requests reconsideration of the present application in view of the foregoing amendments and the following commentary.

### **I. Status of the Claims**

Claims 1-60 were cancelled previously. Claims 86-88 and 123-127 are amended with support in the original specification, for example, at page 15, lines 20-33, the paragraph bridging pages 26 and 27, and at page 67, lines 24-25.

Applicants acknowledge the finality of the outstanding Office Action. Because these amendments (i) are necessitated by the formality objections raised in the final Office Action, (ii) do not require any additional search, and (iii) place the application either in condition for allowance or at least in better condition for appeal, Applicants respectfully request entry of this amendment.

Upon entry, claims 61-127 will be pending, with claims 61-85 and 89-122 withdrawn from examination.

### **II. Statement of the Substance of the Interview**

Applicants thank Examiner Sheridan Swope and Examiner Nashaat Nashed for the courtesies extended during an interview with Applicants' representative, Yang Tang, on May 21, 2008.

During the interview, the objections to the drawings, abstract and the specification were discussed. Examiner Swope clarifies that a SEQ ID NO is required for "EYFP" in the drawings. Since the objections were not raised in the first Office Action, Examiner Swope agreed to consider the necessary amendments in response to the final Office Action upon submission.

In connection with the rejection of claims under 35 U.S.C. §112, first paragraph, for alleged lack of enablement and written description, the Examiners indicated that claims directed to the specific TEV protease and reporter proteins disclosed in the specification would be allowable.

Concerning the rejection of claims under 35 U.S.C. §103(a), the Examiners indicated that further claim amendments and arguments would be considered.

### **III. Objection to the Drawings**

Figures 24 and 25 are objected to for failing to identify a sequence by the SEQ ID NO. Specifically, the Examiner requests that sequence “EYFP” be represented by a SEQ ID NO. Applicants respectfully traverse the grounds of the objection.

In fact, “EYFP” does not represent a polypeptide sequence, as the Examiner contends. Rather, “EYFP” is the abbreviation for “enhanced yellow fluorescent protein” (*see* published application, page 21, paragraph [0380]). As such, no SEQ ID NO is required for figures 24 and 25. Therefore, Applicants respectfully request withdrawal of the objection.

### **IV. Objection to the Abstract**

The abstract is objected to “for being a single, run-on sentence” (final Office Action, page 2, third full paragraph). Applicants respectfully traverse the objection.

Pursuant to MPEP 608.01(b), the language of the abstract should be “clear and concise” and the length of the abstract should not exceed 150 words. There is no requirement of avoiding “a single, run-on sentence” in the abstract however.

In an effort to expedite the prosecution, Applicants submit herewith a rewritten abstract to replace the abstract that the Examiner objects to. Withdrawal of the objection is respectfully requested.

**V. Objection to the Specification**

The specification is objected to for having two sets of figure legends and for lack of section heading. Applicants respectfully traverse the objection.

As set forth in the foregoing amendments to the specification, the description from page 43, line 26, through page 46, line 15, forms "Brief Description of the Drawings." The description from page 46, line 18, through page 57, line 20, constitutes parts of the "Detailed Description of the Invention." Accordingly, section headings have been added in the specification to conform with the formality requirements.

Applicants respectfully request withdrawal of the objection in view of the amendments.

**VI. Rejection of Claims under 35 U.S.C. § 112, second paragraph**

Claims 123 and 125-127 are rejected under 35 U.S.C. § 112, second paragraph, for allegedly being indefinite. Applicants respectfully traverse the rejection.

Specifically, the Examiner rejected the claims for making reference to specific amino acid residues without identifying the sequence by its SEQ ID NO. The claims have been amended to recite a specific protease, the 27 kDa NIa protease of the Tobacco Etch Virus, and to recite the specific positions of the protease. As described in the specification, the NIa protease is well known in the prior art and the sequence of the NIa protease was disclosed at the time of filing the present application. *See* specification, the paragraph bridging pages 26 and 27.

As evidenced by NCBI Accession No. NP\_062908 GI:25013638 (submitted herewith as Exhibit A), the sequence of NIa-Pro protein (from residue 2038 to residue 2279) was disclosed prior to the filing of the present application. The only difference is that the 27 kDa NIa protease of tobacco etch virus has a Gly at the end, i.e., it includes the amino acid at residue 2280.

Otherwise, the sequence is consistent with the 27 kDa NIa protease of tobacco etch virus, e.g., with His at position 46, Asp at position 81, and Cys at position 151.

Therefore, one skilled in the art would have known the positions of the amino acids recited in the claims. Accordingly, Applicants respectfully request withdrawal of the rejection.

**VII. Rejection of Claims under 35 U.S.C. § 112, first paragraph**

Claims 86-88 and 123-127 are rejected under 35 U.S.C. § 112, first paragraph, for alleged lack of enablement and written description. Applicants respectfully traverse the rejection.

Specifically, the Examiner contends that the specification does not support any fragments of any TEV protease and any reporter construct cleavable by the TEV protease. Pursuant to the discussions during the Examiners' interview, the claims have been amended to recite the specific TEV protease, the 27 kDa NIa protease of Tobacco Etach Virus, and the specific reporter proteins, which are supported by the specification.

Moreover, the claims do not encompass any fragments of the protease. Rather, the claims relate to fragments that allow reconstitution of a functional protease via interaction of the interaction partners. As described in the specification, each fragment of the protease alone does not have proteolytic activity, and only upon reconstitution, the proteolytic activity is restored. *See* specification, for example, at page 67, lines 24-25. For greater clarity, the claims have been amended to specify that each fragment of the protease alone does not have protease activity.

In view of the foregoing, Applicants respectfully request withdrawal of the rejection.

**VIII. Rejection of Claims under 35 U.S.C. § 103(a)**

Claims 86-88 remain rejected under 35 U.S.C. § 103(a) for alleged obviousness over Michnick *et al.*, *Methods in Enzymology* 328: 208-230, 2000 ("Michnick"), in view of Bazan *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 7872-7876, 1988 ("Bazan"), and further in view of Carmel *et*

*al.*, *FEBS Letters* 30: 11-14, 1973 (“Carmel”), as evidenced by Stevens, *Structure* 8: R177-R185, 2000 (“Stevens”) and Sawyer *et al.*, *J. Mol. Biol.* 118: 137-208, 1978 (“Sawyer”). Applicants respectfully traverse the rejection.

The teachings of each reference were discussed in the response filed on September 20, 2007. These arguments are incorporated in this response although not explicitly repeated.

In summary, the Examiner’s position is that Bazan discloses the homology between the TEV protease and elastase, both of which have twin  $\beta$ -barrel trypsin-like folds. Therefore, one skilled in the art would be motivated to “make and use two fusion proteins, each comprising a single  $\beta$ -barrel structure, for assaying protein/protein interaction” (final Office Action).

First, Applicants submitted in the prior response that one skilled in the art would not have been motivated to substitute elastase for TEV protease and that the rejection is based on hindsight.

Second, even if the skilled person is motivated to combine the teachings of the cited references, one would have been led down the path that each fusion protein for reconstitution should comprise a single  $\beta$ -barrel structure, as the Examiner presumes in the final Office Action. Based on this presumption, the dividing of the protease would have occurred in the hinge region between the  $\beta$ -barrel domains, i.e., between amino acids 90 and 95. *See* Bazan, figures 2a and 3. In contrast, the specification discloses that the regions that are particularly useful for carrying out the method of invention are at a position between amino acids 60 and 80 or at a position between amino acids 95 and 120. Accordingly, the combined teachings of the references would have not led one skilled in the art to the claimed invention.

Applicants respectfully request withdrawal of the rejection under 35 U.S.C. § 103(a).


CONCLUSION

The present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.



Respectfully submitted,

Date: July 2, 2008

By \_\_\_\_\_

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717



My NCBI [Sign In] [Register]

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search  for

Display   5

Range: from  to  Features: ☒ CDD

☐ 1: [NP\\_062908](#). Reports polyprotein [Toba...[gi:9790345]

BLink, Conserved  
Domains, Links

[Comment](#) [Features](#) [Sequence](#)

LOCUS NP\_062908 3054 aa linear VRL 06-MAY-2008  
DEFINITION polyprotein [Tobacco etch virus].  
ACCESSION NP\_062908  
VERSION NP\_062908.1 GI:9790345  
DBSOURCE REFSEQ: accession [NC\\_001555.1](#)  
KEYWORDS .  
SOURCE Tobacco etch virus  
ORGANISM [Tobacco etch virus](#)  
Viruses; ssRNA positive-strand viruses, no DNA stage; Potyviridae;  
Potyvirus.  
REFERENCE 1 (residues 1 to 3054)  
CONSRM NCBI Genome Project  
TITLE Direct Submission  
JOURNAL Submitted (10-AUG-2000) National Center for Biotechnology  
Information, NIH, Bethesda, MD 20894, USA  
COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The  
reference sequence was derived from [AAA47909](#).  
Draft entry and sequence in computer readable form for [1] and [2]  
kindly provided by R.F.Allison, 28-FEB-1986.  
Method: conceptual translation.

FEATURES Location/Qualifiers  
source 1..3054  
/organism="Tobacco etch virus"  
/db\_xref="taxon:12227"  
Protein 1..3054  
/product="polyprotein"  
/calculated\_mol\_wt=346035  
mat\_peptide 1..304  
/product="P1 protein"  
/name="protease"  
/protein\_id="NP\_734207.1"  
/db\_xref="GI:25013633"  
/calculated\_mol\_wt=34750  
Region 74..303  
/region\_name="Peptidase\_S30"  
/note="Potyvirus P1 protease. The potyviridae family  
positive stand RNA viruses with genome encoding a  
polyprotein. members include zucchini yellow mosaic virus,  
and turnip mosaic viruses which cause considerable losses  
of crops worldwide. This family...; pfam01577"  
/db\_xref="CDD:89550"  
mat\_peptide 305..763  
/product="HC-Pro protein"  
/protein\_id="NP\_734208.1"

Region /db\_xref="GI:25013634"  
/calculated\_mol\_wt=51851  
312..763  
/region\_name="Peptidase\_C6"  
/note="Helper component proteinase. This protein is found  
in genome polyproteins of potyviruses; pfam00851"  
/db\_xref="CDD:64702"

mat\_peptide 764..1110  
/product="P3 protein"  
/protein\_id="NP\_734209.1"  
/db\_xref="GI:25013635"  
/calculated\_mol\_wt=39607

mat\_peptide 1111..1163  
/product="6K1 protein"  
/protein\_id="NP\_734210.1"  
/db\_xref="GI:25013636"  
/calculated\_mol\_wt=6098

mat\_peptide 1164..1796  
/product="CI protein"  
/protein\_id="NP\_734211.1"  
/db\_xref="GI:25013637"  
/calculated\_mol\_wt=70945

Region 1241..1368  
/region\_name="DEXDc"  
/note="DEAD-like helicases superfamily. A diverse family  
of proteins involved in ATP-dependent RNA or DNA  
unwinding. This domain contains the ATP-binding region;  
cd00046"  
/db\_xref="CDD:28927"

Site 1250..1254  
/site\_type="other"  
/note="ATP binding site"  
/db\_xref="CDD:28927"

Site 1336..1339  
/site\_type="other"  
/note="putative Mg++ binding site"  
/db\_xref="CDD:28927"

Region 1424..1522  
/region\_name="HELICc"  
/note="Helicase superfamily c-terminal domain; associated  
with DEXDc-, DEAD-, and DEAH-box proteins, yeast  
initiation factor 4A, Ski2p, and Hepatitis C virus NS3  
helicases; this domain is found in a wide variety of  
helicases and helicase related proteins; may...; cl09953"  
/db\_xref="CDD:99648"

Region 1547..1819  
/region\_name="Poty\_PP"  
/note="Potyviridae polyprotein. This domain is found in  
polyproteins of the viral Potyviridae taxon; pfam08440"  
/db\_xref="CDD:71869"

mat\_peptide 1797..1849  
/product="6K2 protein"  
/protein\_id="NP\_734203.1"  
/db\_xref="GI:25013629"  
/calculated\_mol\_wt=6125

mat\_peptide 1850..2037  
/product="NIa-VPg protein"  
/protein\_id="NP\_734204.1"  
/db\_xref="GI:25013630"  
/calculated\_mol\_wt=21216



mat\_peptide 2038..2279  
 /product="N1a-Pro protein"  
 /protein\_id="NP\_734212.1"  
 /db\_xref="GI:25013638"  
 /calculated\_mol\_wt=27527

Region 2038..2269  
 /region\_name="Peptidase\_C4"  
 /note="Peptidase family C4. This peptidase is present in the nuclear inclusion protein of potyviruses; pfam00863"  
 /db\_xref="CDD:64714"

mat\_peptide 2280..2791  
 /product="N1b protein"  
 /protein\_id="NP\_734205.1"  
 /db\_xref="GI:25013631"  
 /calculated\_mol\_wt=58565

Region 2427..2696  
 /region\_name="RNA\_dep\_RNAP"  
 /note="RNA\_dep\_RNAP: RNA-dependent RNA polymerase (RdRp) is an essential protein encoded in the genomes of all RNA containing viruses with no DNA stage. RdRp catalyzes synthesis of the RNA strand complementary to a given RNA template. RdRps of many viruses...; cd01699"  
 /db\_xref="CDD:73158"

Site order(2527..2532,2589..2590,2625,2627..2628,2670..2671)  
 /site\_type="active"  
 /db\_xref="CDD:73158"

Site order(2527..2528,2627..2628)  
 /site\_type="other"  
 /note="metal ion binding site"  
 /db\_xref="CDD:73158"

Site 2590  
 /site\_type="other"  
 /note="putative nucleic acid binding site"  
 /db\_xref="CDD:73158"

mat\_peptide 2792..3054  
 /product="coat protein"  
 /protein\_id="NP\_734206.1"  
 /db\_xref="GI:25013632"  
 /calculated\_mol\_wt=29644

Region 2818..3054  
 /region\_name="Poty\_coat"  
 /note="Potyvirus coat protein; pfam00767"  
 /db\_xref="CDD:89100"

CDS 1..3054  
 /locus\_tag="TEVgpl"  
 /coded\_by="NC\_001555.1:144..9308"  
 /db\_xref="GeneID:1502321"

ORIGIN

```

1 malifgtvna nilkevfpga rmacvtsahm agangsilkk aeetsraimh kpviifgedyi
61 teadlpytpl hlevdaemer myylgrralt hgkrrkvsvn nkrnrrrkva ktyvgrdsiv
121 ekivvphter kvdttaaved icneattqlv hnsmpkrkkq knflpatsls nvyaqtwsvi
181 rkrhmqvvei skksvrarvk rfegsvqlfa svrhmygerk rvdldridnwq qetlldlacr
241 fknervdqsk ltfgssglvl rggsgypahw yrhgmfvirg rsdgmldvar akvtfavchs
301 mthysdksis eaffipyskk flelrpdgis hecrgvsve rcgevaailt qalspcgkit
361 ckrcmvetpd ivegesgesv tnqgkllaml kegypdfpma ekltrflqq kslvntnlta
421 cvsvkqligd rkqapfthvl avseilfkgn kltgadleea sthmleiarf lnnrtenmri
481 ghlgfvrnk sskahvnnal mcdnqldqng nfiwglrgah akrflkgfft eidpnegydk
541 yvirkhirs rklaignlim stdfqtlrqg iqgetierke ignhcismrn gnyvypcccv
601 tledgkaqys dlkhptkrhl vignsgdsky ldlpvlneek myianegygy mniffallvn
661 vkeedakdft kfirdtivpk lgawptmqdv atacyllsil ypdvlraelp rilvdhdnkt

```

```

721 mhvldsygsr ttgyhmlkmn ttsqliefvh sglesemkty nvvgmnrdrv tggaiemlik
781 siykpnlmkq lleeepyiiv laivspisli amynsgtfeq alqmwlpntm rlanlaails
841 alaqkltlad lfvqqrnlm eyaqvildnl idgvrnhs1 slameivtik latqemdmal
901 reggyavtse kvhemlekny vkalkdawde ltwekfsai rhrskllkfg rkplimkntv
961 dggghidlsv kslfkfhlel lkgtrisavn ggarkvrvak namtkgvflk iysmlpdvyk
1021 fitvssvls1 lltflfqidc mirahreakv aaqlqkesew dniinrtfgy sklenpigyr
1081 staeerlqse hpeafeyykf cigkedlveq akqpeiaayfe kiiafitl1v1 mafdaersdg
1141 vfkilnkfkf gilsstereii ytqslddyvt tfddnmtinl elnmdelhkt slpgvtfkqw
1201 wnnqisrgnv kphyrteghf meftrdtaas vaseishspa rdflvrgavg sgkstglpyh
1261 lskrgvrlml eptrpltdnm hkqlrsepfm cfptlrmrgk stfgsspitv mtsgfalhhf
1321 arniaevkty dfviidechv ndasaiafrn llfehefegk vlkvsatppg revefttqfp
1381 vklkieeals fgefvs1qgt ganadviscg dnilyvyvasy ndvds1gkll vqkgykvski
1441 dgtrmksggt eiitegtsvk khfivatnii engvtididv vvd1fgtkvvp vldvdn1ravq
1501 ynktvvsyge riqklgrvgr hkegvalrig qtnktlveip emvateaafl cfmyn1pvt1t
1561 qsvsttllen atllqartma qfelsyfyti nfvrfdgsmh pvihdklkrf klhtcetfln
1621 klaipnkgls swltsgeykr lgyiaedagi ripfvckeip dslhee1whi vvahkgdsg1i
1681 grltsvqaak vvytlqtdvh siartlacin rriadeqmkq shfeaatgra fsftnysiqs
1741 ifdtlkanya tkhtkeniav lqqakdq1le fsnlakdqdv tgi1qdfn1hl etiylqsdse
1801 vakhlklksh wmksgitr1di iialsvligg gwmlatyfk1d kfnepvfyqg kknqkxhklkm
1861 reargargqy evaaepeale hyfgsaynnk gkrkg1ttrgm gaksrkfinm ygf1dptdfsy
1921 irfvdpl1tgh tidestnapi dl1vqhefgkv rtrmliddei epqslstht1t ihaylvnsgt
1981 kkvlkvdltp hsslrasesk taimgfpere nelrqtgmav pvaydq1lppk nedltfeges
2041 lfkqprdynp isstichltn esdgh1ttsly gigfgpfiit nkhlfrnng t1lvqslhgv
2101 fkvknttt1lq qhlidgrdmi iirmpkdfpp fpqklk1frep greer1clvt tnfqtksmss
2161 mvsdtsctfp ssdg1fwkhw iqt1kdqgcgs plvstrdgfi vgihsasnft nt1nyftsvp
2221 knfmelltnq eaqqwvsgwr l1nads1vlwg hkvmfmskee pfqpvkeatq l1mnelvysqg
2281 ekrkwvveal sgnlrpvaec psq1lvtkhv kgcplfely lq1npekeay fkpmmgaykp
2341 srlnreaf1k dilkyaseie ignvdc1lle laism1v1tkl kalgfptvny itdpee1fsa
2401 lnmkaamgal ykgkkkeals el1t1deqeam lkasc1rlyt gklgiwngs1 kaelrpiekv
2461 ennktrtfta apid1tllagk vc1vddfn1qf ydlnikapwt vgm1tkfyqgw nelmealpsg
2521 wvycdadgsq fdss1ltpfli nav1kvrlaf meewdigeqm l1rnlyteivy tpiltpdg1ti
2581 ikkhkg1nnsq qpst1vvdnt1 mviiamlytc ekcginkee1 v1y1vngdd1l1 iaihpdk1aer
2641 lsrfkesfge lglkyef1dct trdktqlwfm shr1alerdgm yipkleee1ri vsilewdrsk
2701 epshrleaic asmieawgyd klvee1rnfy awvleqapys qlaeegkapy laetalkfly
2761 tsqhgtnsei eeylkvlydy dipttenlyf qsg1tvdagad agkkk1dqkdd kvaegaskdr
2821 dvnagts1gtf svprinamat klqyprmrge v1v1n1nh1lg ykpqqid1sn aratheqfaa
2881 whqavmtayg vneeqmkill ngfmvwcien gts1pn1ngtw vmm1dgedqvs yplkpmvena
2941 qptlrqimth fsd1laeayie mnrerpymp ryglqrnitd m1slsryafdf yel1tsktpvr
3001 areahmqmka aavrns1gtr1 fgldgnvgta eedterhtah dvnrm1ht1l gvrq

```

//

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

Last update: Tue, 29 Apr 2008 Rev. 126150